Non-Hodgkin's lymphoma and the CNS: prophylaxis and therapy in immunocompetent and HIV-positive individuals.
The involvement of the CNS in individuals with non-Hodgkin's lymphoma is a well-recognised complication. Despite the progress that has been made in controlling cancer at most sites in the body, the outcome of individuals affected by meningeal infiltration is dismal and few patients survive for more than a few months. There are few studies that have addressed the management of CNS disease in AIDS-associated non-Hodgkin's lymphoma, and treatment algorithms have been formulated secondary to protocols in immunocompetent individuals. The prevention and treatment of CNS disease is an important aspect of lymphoma management, and new medications, such as a sustained-release formulation of intrathecal cytarabine, will have an increasingly relevant role.
Mazhar
Danish
D
Department of Oncology, The Chelsea and Westminster Hospital, London SW10 9NH, UK.
Stebbing
Justin
J
Bower
Mark
M
D000465:Algorithms; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000627:therapeutic use*; D016543:Central Nervous System Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000517:prevention & control*; D003561:Cytarabine / Q000008:administration & dosage / Q000627:therapeutic use*; D015658:HIV Infections / Q000150:complications*; D006801:Humans; D007121:Immunocompetence; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000473:pathology*; D011379:Prognosis
D000964:Antimetabolites, Antineoplastic; D003561:Cytarabine